All Oncology News

The FDA will increase its flexibility on CMC requirements for cell and gene therapies to speed their development and better support BLA planning.

A BLA for ivonescimab plus chemotherapy in EGFR-mutant NSCLC following treatment with a third-generation EGFR TKI has been submitted to the FDA.

Brian Slomovitz, MD, discusses key trials and surgical advances for patients with ovarian cancer.

FDA announces new CRL for tabelecleucel in EBV+ Post-Transplant Lymphoproliferative Disease.

Experts in the field of CLL/SLL discussed the role of BTK inhibitors and degraders in R/R CLL/SLL during an OncLive Scientific Interchange and Workshop.

Atezolizumab plus bevacizumab could yield superior outcomes compared with TACE in intermediate-stage HCC.

The top 5 OncLive TV videos of the week cover insights in lung cancer, bladder cancer, gastrointestinal cancer, and multiple myeloma.

A rusfertide NDA for polycythemia vera has been submitted to the FDA, a tafasitamab combination boosts PFS over R-CHOP in DLBCL, and more.

Results from ReFocus showed a manageable safety profile and positive antitumor activity for lirafugratinib in FGFR2-mutated cholangiocarcinoma.

Neoadjuvant tislelizumab plus chemoradiotherapy yielded improved response rates in gastric cancer and gastroesophageal junction adenocarcinoma.

Adjuvant pembrolizumab did not improve RFS vs placebo in HCC following complete radiological response after surgical resection or local ablation.

Zolbetuximab plus chemotherapy delivered maximal clinical benefits when AEs were managed effectively in CLDN18.2-positive advanced gastric/GEJ cancer.

CAR-like T-cells, PD-1 inhibitor, and SOX was active in previously untreated metastatic gastric or GEJ adenocarcinoma.

ECOG performance status captured only part of the patient experience in advanced gastric or gastroesophageal junction adenocarcinoma.

Enolen, a localized enzalutamide–eluting implant, has received FDA fast track designation for low- to intermediate-risk, localized prostate cancer.

Pumitamig/nab-paclitaxel produced responses in advanced TNBC in a phase 2 study, informing its further evaluation in the phase 3 ROSETTA Breast-01 trial.

Orca-T improved clinical outcomes both overall and across patient subgroups with varied demographic and clinical features in the Precision-T trial.

Bone marrow Immune Atlas in myeloma linked immune system/tumor interactions with disease aggressiveness, potentially improving prognosis and risk stratification.

Total neoadjuvant chemotherapy plus chemoradiotherapy was identified as a preferred candidate for future study in resectable gastric adenocarcinoma.

Zolbetuximab plus mFOLFOX6 and nivolumab was effective and tolerable across biomarker-defined subgroups in unresectable gastric/GEJ adenocarcinoma.

HERIZON-GEA-01 is the first phase 3 study to demonstrate a median PFS greater than 1 year, and a median OS greater than 2 years in metastatic GEA.

R. Lor Randall, MD, FACS, discusses global variation in DAIR strategies for post–limb salvage infections, highlighting needs for standardization and multidisciplinary coordination.

FDA grants fast track designation to a PARG inhibitor, ETX-19477, for the treatment of BRCA-mutated, platinum-resistant HGSOC.

Zoldonrasib has received breakthrough therapy designation in pretreated KRAS G12D–mutated locally advanced or metastatic NSCLC.

Researchers discovered that the oncogene ERG triggers cancer by reprogramming prostate basal cells.

Preetesh Jain, MD, MBBS, DM, PhD, discusses data from real-world analysis of treatment patterns in high-risk mantle cell lymphoma and their implications.

Fangfang Yan, MD, discusses the place of CAR T-cell therapy in the MCL treatment paradigm and how AI can address drivers of CAR T-cell therapy resistance.

Tsewang Tashi, MD, expands on long-term bone health data with avapritinib in patients with indolent systemic mastocytosis from the PIONEER trial.

Phase 2 data showed atezolizumab plus bevacizumab led to limited responses in patients with metastatic colorectal cancer and an MSI-like gene signature.